SOD1 and amyotrophic lateral sclerosis: Changes in SOD1 concentration in cerebrospinal fluid of ALS patients during treatment provided a basis for using SOD1 activity in cerebrospinal fluid as a biomarker of ALS progression and treatment effectiveness (Gertsman et al., 2019; Winer et al., 2013).